A National Formulary for Canada

Simple item page
dc.contributor.authorHollis, Aidan
dc.contributor.authorLaw, Stephen, M.
dc.date.accessioned2023-03-01T16:01:41Z
dc.date.available2023-03-01T16:01:41Z
dc.description.abstractThis article analyzes the benefits and costs of replacing Canada's ten different provincial formularies with one single national formulary. The 2002 Romanow Commission on the Future of Health Care in Canada recommended that Canada should have a National Drug Agency which would maintain a national formulary, replacing the existing provincial formularies which balkanize drug markets across Canada. This recommendation has been in part incorporated into the "Common Drug Review" in which the provinces (excluding Québec) have agreed to undertake a single evaluation of all new drugs; provinces, however, retain their own formularies and decide which products to list. This balkanized approach to listing and insurance coverage of drugs substantially weakens the bargaining position of the provinces and leads to higher costs.
dc.identifier.urihttps://unbscholar.lib.unb.ca/handle/1882/13105
dc.language.isoEnglish
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subject.disciplineEconomics
dc.titleA National Formulary for Canada
dc.typeworking paper

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
item.pdf
Size:
675.28 KB
Format:
Adobe Portable Document Format
Download

Collections

Working Papers